Witnessing the stock’s movement on the chart, on Wednesday, Keros Therapeutics Inc (NASDAQ: KROS) had a quiet start as it plunged -3.98% to $14.49, before settling in for the price of $15.09 at the close. Taking a more long-term approach, KROS posted a 52-week range of $9.12-$72.37.
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -48.13%. Meanwhile, its Annual Earning per share during the time was -48.13%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 111.69%. This publicly-traded company’s shares outstanding now amounts to $40.62 million, simultaneously with a float of $33.91 million. The organization now has a market capitalization sitting at $588.52 million.
Keros Therapeutics Inc (KROS) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Keros Therapeutics Inc’s current insider ownership accounts for 16.50%, in contrast to 87.64% institutional ownership. According to the most recent insider trade that took place on Oct 15 ’25, this organization’s 10% Owner sold 5,389,264 shares at the rate of 17.75, making the entire transaction reach 95,659,436 in total value, affecting insider ownership by 0.
Keros Therapeutics Inc (KROS) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.96 per share during the current fiscal year.
Keros Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 111.69% and is forecasted to reach -4.39 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 1.55% through the next 5 years, which can be compared against the -48.13% growth it accomplished over the previous five years trading on the market.
Keros Therapeutics Inc (NASDAQ: KROS) Trading Performance Indicators
Let’s observe the current performance indicators for Keros Therapeutics Inc (KROS). It’s Quick Ratio in the last reported quarter now stands at 21.11. Alongside those numbers, its PE Ratio stands at $46.25, and its Beta score is 1.13. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.53. Similarly, its price to free cash flow for trailing twelve months is now 11.09.
In the same vein, KROS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.31, a figure that is expected to reach -1.05 in the next quarter, and analysts are predicting that it will be -4.39 at the market close of one year from today.
